Prof. Sanjay Popat, FRCP, PhD - The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC

Paolo Ghia, MD, PhD - The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations

Julie R. Brahmer, MD, MSc, FASCO - Maximizing the Potential and Expanding the Impact of Immunotherapy in Advanced NSCLC

Komal Jhaveri, MD, FACP - Visual Exploration of the Evolving Role of Novel Oral SERDs, Other ER-Targeting Therapies, and Rational Combinations in ER+, HER2- MBC

Nitin Jain, MD - Committing to Advances for CLL Care: Conversations on Modern Standards of Care and Next-Gen Innovation

Komal Jhaveri, MD, FACP - Changing the Scenery in ER+, HER2- MBC With New Oral SERDs and Combinations: Foundations, Evidence, and Practicalities

Haley A. Moss, MD, MBA / Angeles Alvarez Secord, MD, MHSc - Implementing Immuno-Oncology in Gynecologic Cancer Care for Veterans: Expert Insights on Personalized Treatment

Krish Patel, MD - Mapping Therapeutic Directions in DLBCL: Team Strategies for Prognostic Assessment and Implications for Targeted Therapy and Other Innovative Options

Tanios Bekaii-Saab, MD - Playing the Right Sequence in mCRC: Practical Strategies for Integrating Multi-Kinase Inhibitors in Later Lines of Therapy

Naval Daver, MD, Ghayas Issa, MD - All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes

Grzegorz (Greg) S. Nowakowski, MD, FASCO - Raising Frontline Expectations in DLBCL: Principles for Refining Upfront Treatment and Addressing Unmet Needs With Modern Antibody-Based Combinations

Donna D. Catamero, ANP-BC, OCN, CCRC / Joshua Richter, MD, FACP - At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies

Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc) - Immune to the Impossible in Hepatobiliary Malignancies: Expert Insights on Breakthrough Innovations for Immunotherapy Platforms in Advanced-Stage Disease

Jonathan L. Kaufman, MD - The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies

Caitlin Costello, MD - The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Jennifer Woyach, MD - The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy

Prof. Dr. med. Barbara Eichhorst - The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations

Pier Luigi Zinzani, MD, PhD - Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations